Document:

Exhibit 10.4

 

LOCK-UP AGREEMENT

 

August [   ], 2021

180 Life
Sciences Corp.

 

		Re:	Securities Purchase Agreement, dated as of August 19, 2021 (the “Purchase Agreement”), between
180 Life Sciences Corp. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively,
the “Purchasers”)

 

Ladies and Gentlemen:

 

Defined terms not
otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Purchase
Agreement. Pursuant to Section 2.2(a) of the Purchase Agreement and in satisfaction of a condition of the Company’s obligations
under the Purchase Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until the earlier of (x)
60 days after the Effective Date (provided, that with respect to clause (a) of such definition, only if the Registration Statement registers
for resale all Shares and Warrant Shares) and (y) May 5, 2022 (such period, the “Restriction Period”), the undersigned
will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to,
or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to
cash settlement or otherwise) by the undersigned or any Affiliate of the undersigned or any person in privity with the undersigned or
any Affiliate of the undersigned), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease
a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), with respect to, any shares of Common Stock of the Company or securities convertible, exchangeable or exercisable into,
shares of Common Stock of the Company beneficially owned, held or hereafter acquired by the undersigned (the “Securities”).
Beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. In order to enforce this covenant, the
Company shall impose irrevocable stop-transfer instructions preventing the transfer agent of the Company from effecting any actions in
violation of this Letter Agreement.

 

Notwithstanding
the foregoing, and subject to the conditions below, the undersigned may transfer the Securities provided that (1) the Company receives
a signed lock-up letter agreement (in the form of this Letter Agreement) for the balance of the Restriction Period from each donee, trustee,
distributee, or transferee, as the case may be, prior to such transfer (2) any such transfer shall not involve a disposition for
value, (3) such transfer is not required to be reported with the Securities and Exchange Commission in accordance with the Exchange
Act and no report of such transfer shall be made voluntarily, and (4) neither the undersigned nor any donee, trustee, distributee
or transferee, as the case may be, otherwise voluntarily effects any public filing or report regarding such transfers, with respect to
transfer:

 

	 	i)	as a bona fide gift or gifts;

 

	 	ii)	to any immediate family member or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this Letter Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);

 

     

     

    

  

	 	iii)	to any corporation, partnership, limited liability company, or other business entity all of the equity holders of which consist of the undersigned and/or the immediate family of the undersigned;

 

	 	iv)	if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (a) to another corporation, partnership, limited liability company, trust or other business entity that is an Affiliate of the undersigned or (b) in the form of a distribution to limited partners, limited liability company members or stockholders of the undersigned;

 

	 	v)	if the undersigned is a trust, to the beneficiary of such trust;

 

	 	vi)	by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned; or

 

	 	vii)	of securities purchased in open market transactions after the Closing Date.

   

In addition, notwithstanding
the foregoing, this Letter Agreement shall not restrict the delivery of shares of Common Stock to the undersigned upon (i) exercise any
options granted under any employee benefit plan of the Company; provided that any shares of Common Stock or Securities acquired in connection
with any such exercise will be subject to the restrictions set forth in this Letter Agreement, or (ii) the exercise of warrants; provided
that such shares of Common Stock delivered to the undersigned in connection with such exercise are subject to the restrictions set forth
in this Letter Agreement.

 

Furthermore, the
undersigned may enter into any new plan established in compliance with Rule 10b5-1 of the Exchange Act; provided that (i) such plan may
only be established if no public announcement or filing with the Securities and Exchange Commission, or other applicable regulatory authority,
is made in connection with the establishment of such plan during the Restriction Period and (ii) no sale of shares of Common Stock are
made pursuant to such plan during the Restriction Period.

 

The undersigned
acknowledges that the execution, delivery and performance of this Letter Agreement is a material inducement to each Purchaser to complete
the transactions contemplated by the Purchase Agreement and the Company shall be entitled to specific performance of the undersigned’s
obligations hereunder. The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform
this Letter Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit
from the closing of the transactions contemplated by the Purchase Agreement.

 

    2

     

    

 

This Letter Agreement may
not be amended or otherwise modified in any respect without the written consent of each of the Company and the undersigned. This Letter
Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles of conflict
of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting in the Southern
District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action or proceeding
arising out of or relating to this Letter Agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding,
any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an
inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the
Company at the address in effect for notices to it under the Purchase Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands
that this Letter Agreement does not intend to create any relationship between the undersigned and any Purchaser and that no Purchaser
is entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended
by virtue of this Letter Agreement.

 

This Letter Agreement shall
be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into
a similar agreement for the benefit of the Purchasers.

 

*** SIGNATURE PAGE FOLLOWS***

 

    3

     

    

 

This Letter Agreement may
be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.

 

		 
	Signature	 
		 
	Print Name	 
		 
	Position in Company, if any	 
	 	 
	Address for Notice:	 
	 	 
	 	 
	 	 
		 
	Number of shares of Common Stock	 

 

 

Number of shares of Common
Stock underlying subject to warrants, options, debentures or other convertible securities

 

By signing below, the Company
agrees to enforce the restrictions on transfer set forth in this Letter Agreement.

 

	180 LIFE SCIENCES CORP.	 
	 	 	 
	By:	         	 
	Name: 		 
	Title:		 

 

 

4Exhibit 10.1

 

LIQUID MEDIA GROUP LTD.

 

Common Shares

 

Sales Agreement

August 24, 2021

Virtu Americas LLC

One Liberty Plaza

165 Broadway

New York, NY 10006

 

 

Ladies and Gentlemen:

 

Liquid Media Group
Ltd., a corporation formed under the Business Corporations Act (British Columbia) (the “Company”), confirms
its agreement (this “Agreement”) with Virtu Americas LLC, as sales agent hereunder (the “Agent”),
as follows:

 

1.                
Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms
and subject to the conditions set forth herein, it may issue and sell through or to the Agent, as sales agent, shares (the “Placement
Shares”) of the Company’s common shares, no par value per share (the “Common Shares”), provided,
however, that in no event shall the Company issue or sell through or to the Agent such number of Placement Shares (a) that exceeds
the amount authorized by the Board of Directors of the Company from time to time to be issued and sold under this Agreement, (b) for which
the aggregate offering price exceeds the aggregate dollar amount of Common Shares registered on the Registration Statement (as defined
below) pursuant to which the offering is being made (taking into account all current and future prospectus supplements filed with respect
to the Registration Statement and any post-effective amendments thereto that become effective), (c) that exceeds the dollar amount
of Common Shares permitted to be sold under Form F-3, including General Instruction I.B.5 of Form F-3 to the extent
it remains applicable, or (d) the dollar amount of shares of Common Shares for which the Company has filed a Prospectus (as defined
below)  (the lesser of (a), (b), (c) or (d), the “Maximum Amount”). Notwithstanding anything to the contrary contained
herein, the parties hereto agree that compliance with the limitations set forth in this Agreement regarding the number an aggregate sale
price of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that Agent shall have
no obligation in connection with such compliance. The issuance and sale of Placement Shares through or to Agent will be effected pursuant
to the Registration Statement (as defined below) that was filed by the Company and declared effective by the Securities and Exchange Commission
(the “Commission”), although nothing in this Agreement shall be construed as requiring the Company to use the Registration
Statement to issue Common Shares.

     

     

    

The Company has filed
with the Commission, in accordance with the provisions of the Securities Act of 1933, as amended (the “Securities Act”),
and the rules and regulations thereunder (the “Securities Act Regulations”), a registration statement on Form F-3, including
a base prospectus, relating to certain securities, including the Placement Shares, to be issued from time to time by the Company, and
which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder (the “Exchange
Act Regulations”). The Company has prepared a prospectus supplement (the “Prospectus Supplement”) to the
base prospectus included as part of such registration statement specifically relating to the Placement Shares. The Company will furnish
to Agent, for use by Agent, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus
Supplement, relating to the offer and sale of the Placement Shares hereunder. Except where the context otherwise requires, such registration
statement, as amended on each effective date, and any post-effective amendment thereto that becomes effective, including all documents
filed as part thereof or incorporated by reference therein, except to the extent superseded or modified, and including any information
contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities
Act Regulations or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act Regulations, as
well as any comparable successor registration statement filed by the Company for sale of the Common Shares, including the Placement Shares,
collectively, are herein called the “Registration Statement.” The base prospectus, including all documents incorporated
therein by reference, except to the extent superseded or modified, included in the Registration Statement, as it may be supplemented
by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the
Company with the Commission pursuant to Rule 424(b) under the Securities Act Regulations is herein called the “Prospectus.”
Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to
and include the documents incorporated by reference therein, except to the extent superseded or modified, and any reference herein to
the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement or the
Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to
be incorporated by reference therein (the “Incorporated Documents”).

For purposes of this Agreement,
(a) all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include
the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System (“EDGAR”)
and (b) all currency amounts appearing in this Agreement are presented in United States dollars, or “$”.

Each of the Company and
Agent hereby agree and acknowledge that all sales and solicitations of sales of Common Shares by Agent as agent of the Company shall be
made solely in the United States.

    	 	2	 

     

    

2.                
Placements. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a “Placement”),
it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) containing the parameters in
accordance with which it desires the Placement Shares to be sold, which shall at minimum include the number of Placement Shares to be
issued and sold (a “Placement Notice”), the form of which is attached hereto as Schedule 1. The Placement Notice
shall originate from any of the individuals from the Company set forth on Schedule 2 (with a copy to each of the other individuals
from the Company listed on such schedule), and shall be addressed to each of the individuals from the Agent set forth on Schedule
2, as such Schedule 2 may be amended from time to time. It is expressly acknowledged and agreed that neither the Company nor
the Agent will have any obligation whatsoever with respect to a Placement of any Placement Shares unless and until the Company delivers
a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth below, and then
only upon the terms specified therein and herein. Subject to the foregoing sentence, the Placement Notice shall be effective unless and
until (i) the Agent declines to accept the terms contained therein for any reason, in its sole discretion, by providing email notice
(or other method mutually agreed to in writing by the parties) to the individuals from the Company set forth on Schedule 2, (ii)
the entire amount of the Placement Shares set forth therein have been sold, (iii) the Company or the Agent suspends or terminates the
Placement Notice, (iv) the Company issues a subsequent Placement Notice with parameters superseding those on the earlier Placement Notice,
or (v) the Agreement has been terminated under the provisions of Section 13. The amount of any discount, commission or other compensation
to be paid by the Company to the Agent in connection with the sale of the Placement Shares shall be calculated in accordance with the
terms set forth in Schedule 3. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice,
the terms of the Placement Notice will control.

 

  3.                Sale of Placement Shares by the Agent. Subject to the terms and conditions of this Agreement, for the period specified in a Placement Notice, the Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state, provincial and federal laws, rules and regulations and the rules of the Nasdaq Capital Market (the “Exchange”), to sell the Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. The Agent will provide written confirmation to each of the individuals from the Company set forth on Schedule 2 no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable by the Company to the Agent pursuant to Section 2 with respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Agent (as set forth in Section 5(b)) from the gross proceeds that it receives from such sales. Subject to the terms of the Placement Notice, the Agent may sell Placement Shares only by methods (i) contemplated by Section 4 of British Columbia Instrument 72-503 Distribution of Securities outside British Columbia (“BCI 72-503”), including, without limitation, sales made directly on or through the facilities of an exchange or market outside Canada and (ii) deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including, without limitation, sales made directly on the Exchange or on any other existing trading market for the Common Shares in the United States. The Agent acknowledges and agrees that it will not purchase any Placement Shares on a principal basis pursuant to this Agreement. “Trading Day” means any day on which Common Shares may be purchased and sold on the Exchange.

 

4.                
Suspension of Sales. The Company or the Agent may, upon notice to the other party in writing (including by email correspondence
to each of the individuals of the other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
facsimile transmission or email correspondence to each of the individuals of the other party set forth on Schedule 2), suspend
any sale of Placement Shares; provided, however, that such suspension shall not affect or impair any party’s obligations with respect
to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the parties agrees that no such notice under this
Section 4 shall be effective against any other party unless it is made to one of the individuals
named on Schedule 2 hereto, as such Schedule may be amended from time to time.

    	 	3	 

     

    

		5.	Sale and Delivery to the Agent; Settlement.

 

(a)            
Sale of Placement Shares. On the basis of the representations and warranties herein contained and subject to the
terms and conditions herein set forth, upon the Agent’s acceptance of the terms of a Placement Notice, and unless the sale of the
Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement,
the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading
and sales practices and applicable law and regulations to sell such Placement Shares up to the amount specified, and otherwise in accordance
with the terms of such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be
successful in selling Placement Shares, (ii) the Agent will incur no liability or obligation to the Company or any other person or entity
if it does not sell Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts consistent
with its normal trading and sales practices to sell such Placement Shares as required under this Agreement and (iii) the Agent shall sell
the Placement Shares on an agency basis only and shall not purchase Placement Shares on a principal basis pursuant to this Agreement.

(b)            Settlement
of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement
Shares will occur on the second (2nd) Trading Day (or such earlier day as is then industry practice for regular-way trading of
equity securities in the United States) following the date on which such sales are made (each, a “Settlement
Date”). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares
sold (the “Net Proceeds”) will be equal to the aggregate sales price received by the Agent, after deduction of
(i) the Agent’s commission, discount or other compensation for such sales payable by the Company pursuant to Section 2
hereof, and (ii) any reasonable and documented transaction fees imposed by any governmental or self-regulatory organization in
respect of such sales.

(c)            
Delivery of Placement Shares. On or before each Settlement Date, the Company will, or will cause its transfer agent to,
electronically transfer the Placement Shares being sold by crediting the Agent’s or its designee’s account (provided the
Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository
Trust Company through its Deposit/Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by
the parties hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement
Date, the Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the
Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver
Placement Shares on a Settlement Date, then in addition to and in no way limiting the rights and obligations set forth in Section
11(a) and provided that the Agent has complied with its obligations in Section 3(a), it will (i) hold the Agent harmless against
any loss, claim, damage, or reasonable, documented expense (including reasonable and documented legal fees and expenses), as incurred,
arising out of or in connection with such default by the Company or its transfer agent (if applicable) and (ii) pay to the Agent (without
duplication) any commission, discount, or other compensation to which it would otherwise have been entitled absent such default; provided,
however, that the Company shall not be obligated to pay to the Agent any commission, discount or compensation on any Placement Shares
that are not timely delivered due to (i) a suspension or material limitation in trading in securities generally on the Exchange or (ii)
a material disruption in securities settlement or clearance services in the United States.

    	 	4	 

     

    

(d)           
Limitations on Offering. Under no circumstances shall the Company cause or request the offer or sale of any Placement
Shares if, after giving effect to the sale of such Placement Shares, the aggregate number of Placement Shares sold pursuant to this Agreement
would exceed the lesser of (A) the Maximum Amount and (B) the amount authorized from time to time to be issued and sold under this Agreement
by the Company’s Board of Directors, and notified to the Agent in writing. Under no circumstances shall the Company cause or request
the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time
by the Company’s Board of Directors, and notified to the Agent in writing.

6.                
Representations and Warranties of the Company. The Company represents and warrants to, and agrees with the Agent that, except
as disclosed in the Registration Statement or Prospectus, as of the date of this Agreement and as of each Applicable Time (as defined
below), unless such representation, warranty or agreement specifies a different time or times:

 

(a)          Registration
Statement and Prospectus. The Company and, assuming no act or omission on the part of Agent that would make such statement
untrue, the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form
F-3 under the Securities Act. The Registration Statement has been filed with the Commission and has been declared effective under
the Securities Act. The Prospectus Supplement will name Agent as the agent in the section entitled “Plan of
Distribution.” The Company has not received, and has no notice of, any order of the Commission preventing or suspending the
use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement and the
offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act
Regulations and comply in all material respects with said rule. Any statutes, regulations, document or contracts of a character
required to be described in the Registration Statement or the Prospectus or to be filed as an exhibit to the Registration Statement
have been so described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments or supplements and
all documents incorporated by reference therein that were filed with the Commission on or prior to the date of this Agreement have
been delivered, or are available through EDGAR, to Agent and its counsel. The Company has not distributed and, prior to the later to
occur of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering material
in connection with the offering or sale of the Placement Shares hereunder other than the Registration Statement and the Prospectus
and any Issuer Free Writing Prospectus (as defined below) to which Agent has consented. The Common Shares are currently listed on
the Exchange under the trading symbol “YVR”. Except as disclosed in the Registration Statement, including the Incorporated Documents, or the
Prospectus, the Company has not, in the 12 months preceding the date hereof, received notice from the Exchange to the effect that the
Company is not in compliance with the listing or maintenance requirements. The Company has no reason to believe that it will not in the
foreseeable future continue to be in compliance with all such listing and maintenance requirements, other than compliance with minimum
bid or market capitalization requirements, in respect of which the Company makes no representation or warranty. As of the date of this
Agreement, the Company is subject to the limitations contained in General Instruction I.B.5 of Form F-3.

    	 	5	 

     

    

(b)             
No Misstatement or Omission. The Registration Statement, when it became effective, complied in all material respects with
the requirements of the Securities Act. The Prospectus, as of the date of the Prospectus Supplement, complied, and any amendment or supplement
thereto will comply, on the date thereof, in all material respects with the requirements of the Securities Act. At each Settlement Date,
the Registration Statement and the Prospectus, as of such date, will comply in all material respects with the requirements of the Securities
Act. The Registration Statement, when it became effective, did not, and at each Applicable Time will not, contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
The Prospectus, as of the date of the Prospectus Supplement, and any amendment and supplement thereto, on the date thereof and at each
Applicable Time (defined below), did not or will not include an untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading. The documents incorporated by
reference in the Prospectus did not, and any further documents filed and incorporated by reference therein will not, when filed with the
Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or
necessary to make the statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing
shall not apply to statements in, or omissions from, any such document which are made in reliance upon, and in conformity with, information
furnished to the Company by the Agent specifically for use in the preparation thereof.

(c)              
Conformity of Incorporated Documents. The Incorporated Documents, when such documents were or are filed under the Securities
Act or the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), conformed or will conform in all
material respects with the requirements of the Exchange Act, provided that the Company’s Amendment to its Annual Report on Form
20-F for the year ended November 30, 2020, filed with the Commission on April 15, 2021, which contained restated audited consolidated
financial statements for the years ended November 30, 2020, 2019 and 2018, omitted the eXtensible Business Reporting Language (“XBRL”)
with respect such restated audited consolidated financial statements. The XBRL exhibits were filed with the Commission on August 23,
2021 with Amendment No. 2 to the Company’s Annual Report on Form 20-F for the year ended November 30, 2020.

    	 	6	 

     

    

(d)             
Financial Information. The consolidated financial statements of the Company included or incorporated by reference in the
Registration Statement, the Prospectus and the Issuer Free Writing Prospectus, if any, together with the related notes and schedules,
have been prepared in conformity in all material respects with applicable accounting requirements and the published rules and regulations
of the Commission with respect thereto as in effect as of the time of filing. Such financial statements have been prepared in
accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board and fairly present
in all material respects the consolidated financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated
and the consolidated results of operations and cash flows of the Company at the dates and for the periods specified (subject, in the
case of unaudited statements, to normal year-end audit adjustments which are not material, either individually or in the aggregate);
the other financial data with respect to the Company and the Subsidiaries contained or incorporated by reference in the Registration
Statement, the Prospectus and the Issuer Free Writing Prospectus, if any, are accurately and fairly presented and prepared on a basis
consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma)
that are required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included
or incorporated by reference as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct
or contingent (including any off-balance sheet obligations), not described in the Registration Statement (including the exhibits thereto),
and the Prospectus which are required to be described in the Registration Statement or the Prospectus (including exhibits thereto and
Incorporated Documents); and all disclosures contained or incorporated by reference in the Registration Statement, the Prospectus and
the Issuer Free Writing Prospectus, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules
and regulations of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K
under the Securities Act, to the extent applicable.

(e)              
Conformity with EDGAR Filing. The Prospectus delivered to the Agent for use in connection with the sale of the Placement
Shares pursuant to this Agreement will be identical to the version of the Prospectus transmitted to the Commission for filing via EDGAR,
except to the extent permitted by Regulation S-T.

(f)           
Organization. The Company and any subsidiary that is a significant subsidiary (as such term is defined in Rule 1-02 of
Regulation S-X promulgated by the Commission) (each, a “Subsidiary,” collectively, the “Subsidiaries”),
are, and will be on each Representation Date, duly organized, validly existing as a corporation and in good standing under the laws of
their respective jurisdictions of organization. The Company and each of its Subsidiaries are, and will be on each Representation Date,
duly qualified as a foreign corporation for transaction of business and in good standing under the laws of each other jurisdiction in
which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and
have all corporate power and authority necessary to own or hold their respective properties and to conduct their respective businesses
as described in the Registration Statement and the Prospectus, except, in each case, where the failure to be so qualified or in good
standing or have such power or authority would not or would not reasonably be expected to, individually or in the aggregate, have a material
adverse effect on the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, shareholders’
equity or results of operations of the Company and the Subsidiaries (as defined below) taken as a whole, or prevent or materially interfere
with consummation of the transactions contemplated hereby (a “Material Adverse Effect”).

    	 	7	 

     

    

(g)           Subsidiaries.
The Company’s only Subsidiaries, if any, are set forth, as applicable, on Exhibit 8.1 to the Company’s Annual Report on
Form 20-F or in the Company’s annual information form included as an exhibit to the Company’s Annual Report on Form
40-F, as applicable, in each case, for the Company’s most recently ended fiscal year. The Company owns, directly or
indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance,
right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully paid
and non-assessable.

(h)          
No Violation or Default. Neither the Company nor any of its Subsidiaries is (i) in violation of its notice of articles,
articles or similar organizational documents; (ii) in default, and to the knowledge of the Company no event has occurred that, with
notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition
contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its
Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company
or any of its Subsidiaries are subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of
any court or arbitrator or governmental or regulatory authority, except, in the case of each of clauses (ii) and (iii) above, for any
such violation or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
To the Company’s knowledge, no other party under any material contract or other agreement to which it or any of its Subsidiaries
is a party is in default in any respect thereunder where such default would reasonably be expected to have a Material Adverse Effect.

(i)            
No Material Adverse Effect. Except as disclosed in the Registration Statement or Prospectus, since the date of the most
recent financial statements of the Company included or incorporated by reference into the Registration Statement or Prospectus prior to
each Settlement Date, there has not been (i) any event or condition that has had a Material Adverse Effect, (ii) any material change in
the share capital or outstanding long-term indebtedness of the Company or any of its Subsidiaries, or any dividend or distribution of
any kind declared, paid or made on the capital stock of the Company or any Subsidiary, other than such change, dividend or distribution
which would not have a Material Adverse Effect, and (iii) neither the Company nor any Subsidiary has sustained any material loss or material
interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance
or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority. For each Placement, from
the Applicable Time until the Settlement Date, neither the Company nor any Subsidiary will enter into any transaction or agreement, not
in the ordinary course of business, that is material to the Company or incur any liability, obligation, direct or contingent, not in the
ordinary course of business, that is material to the Company, in each case to the extent such transaction, agreement, liability or obligation
would make the statements in the Registration Statement or Prospectus contain an untrue statement of material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not misleading.

(j)            
Capitalization. The issued and outstanding shares of the capital of the Company have been validly issued, are fully paid
and non-assessable. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration Statement and
the Prospectus as of the dates referred to therein (other than the grant of additional options under the Company’s existing stock
option plans, or changes in the number of outstanding Common Shares of the Company due to the issuance of shares upon the exercise or
conversion of securities exercisable for, or convertible into, Common Shares outstanding on the date hereof or as a result of the issuance of Placement Shares) and
such authorized share capital conforms to the description thereof set forth (or incorporated by reference) in the Registration Statement
and the Prospectus. The description of the Common Shares in the Registration Statement and the Prospectus is complete and accurate in
all material respects. Except as disclosed in or contemplated by the Registration Statement or the Prospectus, as of the date referred
to therein, the Company did not have reserved or available for issuance any Common Shares in respect of options (other than stock options
under the Company’s existing stock option plans), or any rights or warrants to subscribe for, or any securities or obligations convertible
into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of the capital or other securities of or issued
by the Company.

    	 	8	 

     

    

(k)          
Authorization; Enforceability. The Company has full legal right, power and authority to enter into this Agreement and perform
the transactions contemplated hereby. This Agreement has been duly authorized and validly executed and delivered by the Company and is
a legal, valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent that (i) enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by
general equitable principles and (ii) the indemnification and contribution provisions of Section 11 hereof may be limited by federal
or state securities laws and public policy considerations in respect thereof.

(l)            
Authorization of Placement Shares. The Placement Shares, when issued and delivered pursuant to the terms approved by the
Board of Directors of the Company, against payment in full therefor as provided herein, will be duly and validly issued and fully paid
and non-assessable, and will not be subject to preemptive or similar rights. The rights, privileges, restrictions and conditions attaching
to the Placement Shares, when issued, will conform in all material respects to the description thereof set forth in or incorporated into
the Prospectus.

(m)         
No Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or
arbitrator or any governmental or regulatory authority is required for the execution, delivery and performance by the Company of this
Agreement, and the issuance and sale by the Company of the Placement Shares as contemplated hereby, except for (i) such consents, approvals,
authorizations, orders, exemptions, decisions and registrations or qualifications as may be required under applicable state securities
laws, by the by-laws and rules of the Financial Industry Regulatory Authority (“FINRA”) or by the Exchange in connection
with the sale of the Placement Shares by the Agent, or (ii) the filing with the Commission of the Prospectus Supplement and any Current
Reports on Form 6-K with respect to this Agreement and the transactions contemplated hereby.

(n)          
No Preferential Rights. (i) No person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under
the Securities Act (each, a “Person”), has the right, contractual or otherwise, to cause the Company to issue or sell
to such Person any Common Shares or shares of any other capital stock or other securities of the Company (other than upon the exercise
of options or warrants to purchase Common Shares or upon the exercise of options that may be granted from time to time under the Company’s
stock option plans), (ii) no Person has any preemptive rights, rights of first refusal, or any other rights(whether pursuant to a
“poison pill” provision or otherwise) to purchase any Common Shares or shares of any other capital stock or other securities
of the Company from the Company which have not been duly waived with respect to the offering contemplated hereby, (iii) 
except as disclosed in writing to Agent or its representatives in connection with the transactions contemplated hereby, no Person has
the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Common Shares
(excluding, for greater certainty, Agent), and (iv) no Person has the right, contractual or otherwise, to require the Company to
register under the Securities Act any Common Shares or shares of any other capital stock or other securities of the Company, or to include
any such shares or other securities in the Registration Statement or the offering contemplated thereby, whether as a result of the filing
or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated hereby, except for such rights as have
been waived on or prior to the date hereof.

    	 	9	 

     

    

(o)          
Independent Public Accountant. Davidson & Company LLP (the “Accountant”), whose report on the consolidated
financial statements of the Company is filed with the Commission as part of the Company’s most recent Annual Report on Form 20-F
or Form 40-F, as applicable, filed with the Commission and incorporated into the Registration Statement, is and, during the periods covered
by its report, was an independent public accountant within the meaning of the Securities Act and the Public Company Accounting Oversight
Board (United States).

(p)          
No Litigation. Except as disclosed in the Registration Statement or Prospectus, there are no legal, governmental or regulatory
actions, suits or proceedings pending, nor, to the Company’s knowledge, any legal, governmental or regulatory investigations, to
which the Company or a Subsidiary is a party or to which any property of the Company or any of its Subsidiaries is the subject that, individually
or in the aggregate, would reasonably be expected to have a Material Adverse Effect or materially and adversely affect the ability of
the Company to perform its obligations under this Agreement; except as disclosed in the Registration Statement or Prospectus, to the Company’s
knowledge, no actions, suits or proceedings are threatened or contemplated by any governmental or regulatory authority or threatened by
others that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; and there are no current
or pending legal, governmental or regulatory, actions, suits, proceedings or, to the Company’s knowledge, investigations that are
required under the Securities Act to be described in the Prospectus that are not described in the Prospectus.

(q)          
Licenses and Permits. The Company and each of its Subsidiaries possess or have obtained, all licenses, certificates, consents,
orders, approvals, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal,
state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties
or the conduct of their respective businesses as described in the Registration Statement and the Prospectus (the “Permits”),
except where the failure to possess, obtain or make the same would not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect. Except as disclosed in the Registration Statement or the Prospectus, neither the Company nor any of its Subsidiaries
have received written notice of any proceeding relating to revocation or modification of any such Permit or has any reason to believe
that such Permit will not be renewed in the ordinary course, except where such revocation, modification or failure to obtain any such
renewal would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

    	 	10	 

     

    

(r)           
 No Material Defaults. Neither the Company nor any of the Subsidiaries is in default under any indenture or credit agreement
in respect of indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the
aggregate, would reasonably be expected to have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a)
or 15(d) of the Exchange Act since the filing of its last Annual Report on Form 20-F or Form 40-F, as applicable, indicating that it (i) has
failed to pay any dividend or sinking fund installment on preferred stock or (ii) has defaulted on any installment on indebtedness
for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably
be expected to have a Material Adverse Effect.

(s)           
Certain Market Activities. Neither the Company, nor any of the Subsidiaries, nor any of their respective directors, officers
or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably be expected
to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Placement Shares.

(t)            
Broker/Dealer Relationships. Neither the Company nor any of the Subsidiaries or any related entities (i) is required
to register as a “broker” or “dealer” in accordance with the provisions of the Exchange Act or (ii) directly
or indirectly through one or more intermediaries, controls or is a “person associated with a member” or “associated
person of a member” (within the meaning set forth in the FINRA Manual).

(u)          
No Reliance. The Company has not relied upon Agent or legal counsel for Agent for any legal, tax or accounting advice in
connection with the offering and sale of the Placement Shares.

(v)          
Taxes. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have
been required to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and
are not being contested in good faith, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect.
Except as otherwise disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined
adversely to the Company or any of its Subsidiaries which has had a Material Adverse Effect. The Company has no knowledge of any federal,
state or other governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would
reasonably be expected to have a Material Adverse Effect.

(w)          Title
to Real and Personal Property. Neither the Company nor its Subsidiaries own real property. The Company and its Subsidiaries have
good and valid title to all personal property (excluding Intellectual Property, which is addressed below) described in the
Registration Statement or Prospectus as being owned by them that are material to the businesses of the Company or such Subsidiary,
in each case free and clear of all liens, encumbrances and claims, except those that (i) do not materially interfere with the
use made and proposed to be made of such property by the Company and any of its Subsidiaries or (ii) would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect. Any real property described in the Registration
Statement or Prospectus as being leased by the Company and any of its Subsidiaries is held by them under valid, existing and
enforceable leases, except those that (A) do not materially interfere with
the use made or proposed to be made of such property by the Company or any of its Subsidiaries or (B) would not be reasonably expected,
individually or in the aggregate, to have a Material Adverse Effect.

    	 	11	 

     

    

(x)          
Intellectual Property. The Company and its Subsidiaries own or have obtained adequate enforceable rights to use all patents,
patent applications, trademarks (both registered and unregistered), service marks, trade names, trademark registrations, service mark
registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) (collectively, the “Intellectual Property”), necessary for the conduct of their
respective businesses as conducted as of the date hereof, except to the extent that the failure to own or to have obtained adequate rights
to use such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
except as disclosed in writing to Agent, neither the Company nor any of its Subsidiaries has received any written notice of any claim
of infringement or conflict which asserted Intellectual Property rights of others, which infringement or conflict would reasonably be
expected to result in a Material Adverse Effect; there are no pending, or to the Company’s knowledge, threatened judicial proceedings
or interference proceedings against the Company or its Subsidiaries challenging the Company’s or its Subsidiaries’ rights
in or to or the validity of the scope of any of the Company’s or its Subsidiaries’ material patents, patent applications or
proprietary information, except for such proceedings which would not reasonably be expected to have a Material Adverse Effect; to the
Company’s knowledge, no other entity or individual has any right or claim in any of the Company’s or its Subsidiaries’
owned material patents, patent applications or any patent to be issued therefrom by virtue of any contract, license or other agreement
entered into between such entity or individual and the Company or a Subsidiary or by any non-contractual obligation of the Company or
a Subsidiary, other than by written licenses granted by the Company or a Subsidiary, except for such rights or claims which would not
reasonably be expected to have a Material Adverse Effect; the Company and its Subsidiaries have not received any written notice of any
claim challenging the rights of the Company or a Subsidiary in or to any Intellectual Property owned, licensed or optioned by the Company
or such Subsidiary which claim would reasonably be expected to result in a Material Adverse Effect.

(y)          
Compliance with Applicable Laws. The Company has not been advised, and has no reason to believe, that it and each of its
Subsidiaries are not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it
is conducting business, except where failure to be so in compliance would not reasonably be expected to result in a Material Adverse Effect.

(z)           
Environmental Laws. The Company and its Subsidiaries (i) are in compliance with any and all applicable federal, state,
local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment
or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (ii) have
received and are in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct
their respective businesses as described in the Registration Statement and the Prospectus; and (iii) have not received written notice
of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances
or wastes, pollutants or contaminants, except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply
or failure to receive required permits, licenses, other approvals or notice
or liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

    	 	12	 

     

    

(aa)        
Disclosure Controls. The Company maintains disclosure controls and procedures and internal controls over financial reporting
(each as defined in Rule 13a-15 under the Exchange Act) that comply with the requirements of the Exchange Act. The Company is not aware
of any material weaknesses in its internal control over financial reporting (other than as set forth (or incorporated by reference) in
the Registration Statement or Prospectus). Since the date of the latest audited financial statements of the Company included in the Prospectus,
there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably
likely to materially affect, the Company’s internal control over financial reporting, and are required to have been disclosed in
previously filed reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act
and the Exchange Act but have not been disclosed therein. The Company’s certifying officers have evaluated the effectiveness of
the Company’s disclosure controls and procedures as of a date within 90 days prior to the filing date of the Annual Report on Form
20-F or Form 40-F, as applicable, for the fiscal year most recently filed with the Commission (such date, the “Evaluation Date”).
The Company presented in its Annual Report on Form 20-F or Form 40-F, as applicable, most recently filed with the Commission the conclusions
of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date.

(bb)       
Sarbanes-Oxley. Except as set forth in the Registration Statement or Prospectus, there is and has been no failure on the
part of the Company or, to the knowledge of the Company, any of the Company’s directors or officers, in their capacities as such,
to comply with any applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. Each
of the principal executive officer and the principal financial officer of the Company (or each former principal executive officer of the
Company and each former principal financial officer of the Company as applicable) has made all certifications required by Sections 302
and 906 of the Sarbanes-Oxley Act. For purposes of the preceding sentence, “principal executive officer” and “principal
financial officer” shall have the meanings given to such terms in the Sarbanes-Oxley Act.

(cc)        
Finder’s Fees. Neither the Company nor any of the Subsidiaries has incurred any liability for any finder’s fees,
brokerage commissions or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with
respect to Agent pursuant to this Agreement.

(dd)       
Labor Disputes. Except as disclosed in the Registration Statement or Prospectus, no labor disturbance by or dispute with
employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is threatened, in either case which would
reasonably be expected to result in a Material Adverse Effect

(ee)        
Investment Company Act. The Company, after giving effect to the offering and sale of the Placement Shares, will not be an
“investment company” or an entity “controlled” by an “investment company,” as such terms are defined
in the Investment Company Act of 1940, as amended (the “Investment Company Act”).

    	 	13	 

     

    

(ff)         
 Operations. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in
all material respects with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”), except as would
not reasonably be expected to result in a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws
is pending or, to the knowledge of the Company, threatened.

(gg)       
Off-Balance Sheet Arrangements. Except as disclosed in the Registration Statement or Prospectus, there are no transactions,
arrangements and other relationships between and/or among the Company, and/or, to the knowledge of the Company, any of its Subsidiaries
and any unconsolidated entity, including, but not limited to, any structural finance, special purpose or limited purpose entity (each,
an “Off Balance Sheet Transaction”) that would reasonably be expected to affect materially the Company’s liquidity
or the availability of or requirements for its capital resources.

(hh)       
Underwriter Agreements. The Company is not a party to any agreement with an agent or underwriter for any other “at-the-market”
transaction under Rule 415 of the Securities Act.

(ii)          
ERISA. To the knowledge of the Company, (i) each material employee benefit plan, within the meaning of Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended (“ERISA”), that is maintained, administered or contributed
to by the Company or any of its Subsidiaries (other than a Multiemployer Plan, within the meaning of Section 3(37) of ERISA) for employees
or former employees of the Company and any of its Subsidiaries has been maintained in material compliance with its terms and the requirements
of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Internal Revenue Code of 1986, as
amended (the “Code”); (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of
the Code, has occurred which would result in material liability to the Company with respect to any such plan (excluding transactions effected
pursuant to a statutory or administrative exemption); and (iii) for each such plan that is subject to the funding rules of Section 412
of the Code or Section 302 of ERISA, no “accumulated funding deficiency” as defined in Section 412 of the Code has been incurred,
whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions)
equals or exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions, other than,
in the case of (i), (ii) and (iii) above, as would not reasonably be expected to have a Material Adverse Effect.

(jj)          
Insurance. The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such
risks as the Company believes are adequate for the conduct of their businesses and customary for companies of similar size engaged in
similar businesses in similar industries.

    	 	14	 

     

    

(kk)       
 No Improper Practices. (i) Neither the Company nor, to the Company’s knowledge, the Subsidiaries, nor to the
Company’s knowledge, any of their respective executive officers has, in the past five years, made any unlawful contributions to
any candidate for any political office (or failed fully to disclose any contribution in violation of law) or made any contribution or
other payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar
public or quasi-public duty in violation of any law; (ii) no relationship, direct or indirect, exists between or among the Company or,
to the Company’s knowledge, any Subsidiary, or any affiliate of them, on the one hand, and the directors, officers and stockholders
of the Company or, to the Company’s knowledge, any Subsidiary, on the other hand, that is required by the Securities Act to be described
in the Registration Statement and the Prospectus that is not so described; (iii) the Company has not offered, or caused any placement
agent to offer, Common Shares to any person with the intent to influence unlawfully (A) a customer or supplier of the Company or
any Subsidiary to alter the customer’s or supplier’s level or type of business with the Company or any Subsidiary or (B) a
trade journalist or publication to write or publish favorable information about the Company or any Subsidiary or any of their respective
products or services, and, (iv) neither the Company nor any Subsidiary nor, to the Company’s knowledge, any employee or agent of
the Company or any Subsidiary has made any payment of funds of the Company or any Subsidiary or received or retained any funds in violation
of the Foreign Corrupt Practices Act of 1977.

(ll)          
Status Under the Securities Act. The Company was not and will not be at any Settlement Date an ineligible issuer as defined
in Rule 405 under the Securities Act.

(mm)    
No Conflicting Statements in an Issuer Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date
and as of each Applicable Time (as defined in Section 24 below), did not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated
document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to conflicting information
in any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by Agent specifically
for use therein.

(nn)       
No Conflicts. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the
consummation of any of the transactions contemplated herein, nor the compliance by the Company with the terms and provisions hereof will
conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a default under,
or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the
Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of the property or
assets of the Company is subject, except (i) such conflicts, breaches or defaults as may have been waived and (ii) such conflicts, breaches
and defaults that would not reasonably be expected to have a Material Adverse Effect; nor will such action result (x) in any violation
of the provisions of the organizational or governing documents of the Company, or (y) in any material violation of the provisions of any
statute or any order, rule or regulation applicable to the Company or of any court or of any federal, state or other regulatory authority
or other government body having jurisdiction over the Company, except where such violation would not reasonably be expected to have a
Material Adverse Effect.

    	 	15	 

     

    

(oo)       
 OFAC. (i) To the knowledge of the Company, neither the Company nor any of its Subsidiaries (collectively, the “Entity”),
nor any director, officer, employee, agent or representative of the Entity, is an individual or entity (in this paragraph (oo), “Person”)
that is, or is owned or controlled by a Person that is:

(A)  the
subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”),
the European Union (“EU”) or other relevant sanctions authority (collectively, “Sanctions”), or

(B)  located,
organized or resident in a country or territory that is the subject of Sanctions.

(ii)  The
proceeds of the issuance and sale of the Placement Shares will be applied by the Entity in good faith as described under the caption “Use
of Proceeds” in each Prospectus Supplement and the Prospectus, and not with the result that any Person, directly or indirectly,
shall have used the proceeds of the offering, or lent, contributed or otherwise made available such proceeds to any subsidiary, joint
venture partner or other Person:

(A)  to fund
or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation,
is the subject of Sanctions; or

(B)  in any
other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as
underwriter, advisor, investor or otherwise).

(iii)  Except
as described in the Registration Statement and the Prospectus, during the past 5 years, the Entity has not knowingly engaged in or is
not now knowingly engaged in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing
or transaction is or was the subject of Sanctions.

(pp)       
Stock Transfer Taxes. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required
to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid
or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with in all material respects.

(qq)       
Foreign Private Issuer. The Company is a “foreign private issuer” as such term is defined in Rule 3b-4 under
the Exchange Act and in Rule 405 under the Securities Act.

    	 	16	 

     

    

(rr)          Cybersecurity.
To the knowledge of the Company and its Subsidiaries, there has been no security breach or incident, unauthorized access or
disclosure, or other compromise of or relating to the Company’s or its Subsidiaries’ information technology and computer
systems, networks, hardware, software, data and databases (including, without limitation, the data and information of their
respective customers, employees, suppliers and vendors and any third party data maintained, processed or stored by the Company and
its Subsidiaries, and any such data processed or stored by third parties on behalf of the Company and its Subsidiaries), equipment
or technology (collectively, “IT Systems and Data”); neither the Company nor its Subsidiaries has been notified
of, or has knowledge of any event or condition that would result in, any security breach or incident, unauthorized access or
disclosure or other compromise to their IT Systems and Data; the Company and its Subsidiaries have implemented appropriate controls,
policies, procedures, and technological safeguards to maintain and protect the integrity, continuous operation, redundancy and
security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required by applicable
regulatory standards; and the Company and its Subsidiaries are presently in material compliance with all applicable laws or statutes
and all judgments and orders of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from
unauthorized use, access, misappropriation or modification, except, in each case, where the failure to be in such material
compliance would not or would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect.

Any certificate signed
by an authorized officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with this
Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set forth
therein.

 

7.                
Covenants of the Company. The Company covenants and agrees with the Agent that:

 

(a)                
Registration Statement Amendments. After the date of this Agreement and during any period in which a Prospectus relating
to any Placement Shares is required to be delivered by Agent under the Securities Act (including in circumstances where such requirement
may be satisfied pursuant to Rule 172 under the Securities Act) (the “Prospectus Delivery Period”), (i) the Company
will notify Agent promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated
by reference or amendments not related to any Placement, has been filed with the Commission and/or has become effective or any subsequent
supplement to the Prospectus has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement
or Prospectus or for additional information related to the Placement, (ii) the Company will not file any amendment or supplement
to the Registration Statement or Prospectus relating to the Placement Shares, other than documents incorporated by reference, unless a
copy thereof has been submitted to Agent within a reasonable period of time before the filing and Agent has not reasonably objected thereto
(provided, however, (A) that the failure of Agent to make such objection shall not relieve the Company of any obligation or liability
hereunder, or affect Agent’s right to rely on the representations and warranties made by the Company in this Agreement, (B) that
the Company has no obligation to provide Agent any advance copy of such filing or to provide Agent an opportunity to object to such filing
if such filing does not name Agent or does not relate to the transactions contemplated hereunder, and (C) that the only remedy Agent shall
have with respect to the failure by the Company to provide Agent with such copy shall be to cease making sales under this Agreement) and
the Company will furnish to Agent at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by
reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iii) the Company will
cause each amendment or supplement to the Prospectus, other than documents incorporated by reference, to be filed with the Commission
as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any document
to be incorporated therein by reference, to be filed with the Commission as required pursuant to the Exchange Act, within the time period
prescribed (the determination to file or not file any amendment or supplement with the Commission under this Section 7(a), based on the
Company’s reasonable opinion or reasonable objections, shall be made exclusively by the Company).

    	 	17	 

     

    

(b)                
Notice of Commission Stop Orders. During the Prospectus Delivery Period, the Company will advise the Agent promptly after
it receives notice or obtains knowledge thereof of the issuance or threatened issuance by the Commission of any stop order suspending
the effectiveness of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in
any jurisdiction, or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially
reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company
will advise the Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or any
amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering
of the Placement Shares or for additional information related to the Registration Statement, the Prospectus or any Issuer Free Writing
Prospectus.

(c)                
Delivery of Prospectus; Subsequent Changes. If during the Prospectus Delivery Period any event occurs as a result of which
the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in the light of the circumstances then existing, not misleading, or if during the Prospectus Delivery
Period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company
will promptly notify the Agent to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement
the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance.

(d)                
Listing of Placement Shares. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts
to cause the Placement Shares to be conditionally accepted for listing on the Exchange.

(e)                
Delivery of Registration Statement and Prospectus. The Company will furnish to the Agent and its counsel (at the expense
of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all
amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus Delivery
Period (including all documents filed with the Commission during such period that are deemed to be incorporated by reference therein)
in each case as soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the
Agent’s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may
be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus, but excluding any
document incorporated therein by reference) to the Agent to the extent such document is available on EDGAR.

 

    	 	18	 

     

    

(f)                 
                                            Earnings Statement. The Company will make generally available to its security
                                            holders not later than 15 months after the end of the Company’s current fiscal quarter,
                                            an earnings statement covering a 12-month period for the purposes of, and to provide to the
                                            Agent the benefits contemplated by, the last paragraph of Section 11(a) and Rule 158 of
                                            the Securities Act. For the avoidance of doubt, the Company’s
                                            compliance with the reporting requirements of the Exchange Act
                                            shall be deemed to satisfy the requirements of this Section 4(d).

 

(g)                
 Use of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use
of Proceeds.”

 

(h)                
Notice of Other Sales. During the pendency of any Placement Notice given hereunder, the Company shall provide the Agent
with written notice as promptly as reasonably possible before it will, directly or indirectly, offer to sell, sell, contract to sell,
grant any option to sell or otherwise dispose of any Common Shares (other than the Placement Shares offered pursuant to this Agreement)
or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares; provided,
however, that such notice will not be required in connection with the Company’s issuance, grant or sale of (i) Common Shares, options
to purchase Common Shares or Common Shares issuable upon the exercise of options, pursuant to any employee or director stock option or
benefits plan, stock ownership plan or dividend reinvestment plan (but not Common Shares subject to a waiver to exceed plan limits in
its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented; (ii) other equity incentive awards approved
by the Board of Directors of the Company or the compensation committee thereof or the issuance of Common Shares upon the exercise or settlement
thereof; (iii) Common Shares issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or
disclosed as outstanding in the Registration Statement or the Prospectus; (iv) the issuance of securities in connection with an acquisition,
merger or sale or purchase of assets; and (v) Common Shares, or securities convertible into or exercisable for Common Shares, issued pursuant
to consulting arrangements or service provider arrangements the primary purpose of which is not to raise capital. In addition, while this
Agreement is in force and shall not have expired, terminated or been terminated, during the period beginning on the fifth (5th) Trading
Day immediately prior to the date on which any Placement Notice is delivered to the Agent hereunder and ending on the fifth (5th) Trading
Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the
Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of
such suspension or termination), the Company will not, directly or indirectly, sell, contract to sell, grant any option to sell or otherwise
dispose of any Common Shares (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable
for Common Shares, warrants or any rights to purchase or acquire, Common Shares in any other “at-the-market” offering.

 

(i)                 
Change of Circumstances. The Company will, at any time during the pendency of a Placement Notice given hereunder, advise
the Agent promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect
in any material respect any opinion, certificate, letter or other document required to be provided to the Agent pursuant to this Agreement.

 

    	 	19	 

     

    

 

(j)                 
Due Diligence Cooperation. The Company will cooperate with any reasonable due diligence review conducted by the Agent or
its representatives in connection with the transactions contemplated hereby, including, without limitation, providing information and
making available documents and senior corporate officers, during regular business hours, upon reasonable advance written notice and at
the Company’s principal offices, as the Agent may reasonably request.

 

(k)                
Required Filings Relating to Placement of Placement Shares. The Company agrees to disclose in its quarterly reports, annual
information form or annual report on Form 20-F or Form 40-F, as applicable, the amount of Placement Shares sold through or to the Agent,
the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares.

 

(l)                 
Representation Dates; Certificate. On or prior to the delivery of the first Placement Notice and each time the Company subsequently:

 

(i)                                                     
files a Prospectus relating to the offer and sale of the Placement Shares, amends the Registration Statement by means of a post-effective
amendment or amends or supplements the Prospectus relating to the offer and sale of the Placement Shares (other than a prospectus supplement
relating solely to an offering of securities other than the Placement Shares) by means of a sticker or supplement, but not by means of
incorporation of documents by reference into the Registration Statement or the Prospectus relating to the Placement Shares;

 

(ii)                                                
files an annual report on Form 20-F or Form 40-F under the Exchange Act (including any Form 20-F/A or Form 40-F/A that contains
restated financial statements); or

 

(iii)                                           
furnishes its unaudited interim financial statements and management’s discussion and analysis on Form 6-K under the Exchange
Act (each date of filing of one or more of the documents referred to in clauses (i) through (iii) shall be a “Representation
Date”);

 

the Company shall
furnish the Agent with a certificate, in the form attached hereto as Exhibit 7(l) within five (5) Trading Days. The requirement to provide
a certificate under this Section 7(l) shall be waived for any Representation Date occurring during a fiscal quarter during which
the Company does not intend to sell Placement Shares prior to the next occurring Representation Date; provided, however, that such waiver
shall not apply for any Representation Date on which the Company files its annual report on Form 20-F or Form 40-F, as applicable. Notwithstanding
the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on
such waiver and did not provide the Agent with a certificate under this Section 7(l), then before the Company delivers the Placement
Notice or the Agent sells any Placement Shares, the Company shall provide the Agent with a certificate, in the form attached hereto as
Exhibit 7(l), dated the date of the Placement Notice.

 

    	 	20	 

     

    

(m)              
Legal Opinions. (1) On or prior to the delivery of the first Placement Notice, and (2) within five (5) Trading Days after
each Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit
7(l) for which no waiver is applicable, the Company shall cause to be furnished to the Agent written opinions of Katten Muchin Rosenman
LLP (“US Company Counsel”) and Miller Thomson LLP (“Canadian Company Counsel”), or other counsel reasonably
satisfactory to the Agent, each in form and substance reasonably satisfactory to the Agent, modified, as necessary, to relate to the
Registration Statement and the Prospectus, as then amended or supplemented; provided, however, that in lieu of such opinions for Representation
Dates after the date hereof, US Company Counsel and Canadian Company Counsel may each furnish the Agent with a letter (a “Reliance
Letter”) to the effect that the Agent may rely on a prior opinion delivered under this Section 7(m) to the same extent
as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration
Statement and the Prospectus, as amended or supplemented as of the date of the Reliance Letter).

 

(n)                
Comfort Letter. (1) On or prior to the delivery of the first Placement Notice and (2) within five (5) Trading Days after
the filing by the Company of an annual report on Form 20-F or Form 40-F under the Exchange Act, for which no waiver is applicable, the
Company shall cause its independent accountants to furnish the Agent letters (the “Comfort Letters”), dated the date
the Comfort Letter is delivered, which shall meet the requirements set forth in this Section 7(n). The Comfort Letter from the
Company’s independent accountants shall be in a form and substance reasonably satisfactory to the Agent, (i) confirming that they
are an independent public accounting firm within the meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the conclusions
and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants’ “comfort
letters” to underwriters in connection with registered public offerings (the first such letter, the “Initial Comfort Letter”)
and (iii) updating the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it
been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented
to the date of such letter.

(o)                
Market Activities. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or
that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the Placement Shares or (ii) sell, bid for, or purchase Common Shares in violation of Regulation
M under the Exchange Act, as applicable, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the
Agent; provided, however, that the Company may bid for and purchase its Common Shares in accordance with Rule
10b-18 under the Exchange Act; and provided further, that no such bids or purchases shall be made by the Company during the three (3)
Trading Days before or after any sale of any Placement Shares pursuant to this Agreement.

 

(p)                
Investment Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it
nor any of its Subsidiaries will be or become, at any time prior to the termination of this Agreement, an “investment company,”
as such term is defined in the Investment Company Act, assuming no change in the Commission’s current interpretation as to entities
that are not considered an investment company.

 

(q)                 No
Offer to Sell. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agent in its capacity as
agent hereunder, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity
as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the
Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy
Placement Shares hereunder.

    	 	21	 

     

    

 

(r)                 
Sarbanes-Oxley Act. The Company and the Subsidiaries will use their best efforts to maintain disclosure controls and procedures
and internal controls over financial reporting (each as defined in Rule 13a-15 under the Exchange Act) that comply with the requirements
of the Exchange Act.

The Agent
may, in its sole discretion, waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the
time for their performance.

 

8.                
Representations and Covenants of the Agent. The Agent represents, warrants and covenants to the Company that it is duly
registered as a broker-dealer under FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement
Shares will be offered and sold, except such states in which the Agent is exempt from registration or such registration is not otherwise
required, and, for greater certainty, the Agent will not knowingly offer or sell Placement Shares to a resident of Canada. The Agent shall
continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable statutes
and regulations of each state in which the Placement Shares will be offered and sold, except such states in which the Agent is exempt
from registration or such registration is not otherwise required, during the term of this Agreement. The Agent will comply with all applicable
law and regulations in connection with the Placement Shares, including but not limited to Regulation M under the Exchange Act.

 

		9.	Payment of Expenses.

 

The Company will pay
all expenses incident to the performance of its obligations under this Agreement, including: (i) the preparation, filing, including any
fees required by the Commission, and printing of the Registration Statement (including financial statements and exhibits) as originally
filed and of each amendment and supplement thereto and each Issuer Free Writing Prospectus, in such number as the Agent shall reasonably
deem necessary, (ii) the preparation, issuance and delivery of the certificates, if any, for the Placement Shares to the Agent including
any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes (other than income taxes) payable upon
the sale, issuance or delivery of the Placement Shares to the Agent, (iii) the fees and disbursements of the Company’s counsel,
accountants and other advisors, (iv) the actual and documented fees and expenses of the transfer agent and registrar for the Placement
Shares, (v) the filing fees incident to any review by FINRA of the terms of the sale of the Placement Shares, (vi) the fees and disbursements
of counsel to the Agent in an amount not to exceed $50,000, and (vii) the fees and expenses incurred in connection with the listing of
the Placement Shares on the Exchange.

 

10.             
Conditions to the Agent’s Obligations. The obligations of the Agent hereunder with respect to a Placement will be
subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance
by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to them in their reasonable
judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:

    	 	22	 

     

    

 

(a)              
Registration Statement Effective. The Registration Statement shall have become effective and shall be available for the
sale of all Placement Shares contemplated to be issued by any Placement Notice.

 

(b)             
No Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any
request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement the response to which would require any post- effective amendments or supplements to the Registration Statement
or the Prospectuses; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of
any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for
sale hereunder in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or

(iv) the occurrence of any event that
requires the making of any changes in the Registration Statement, the Prospectuses or material documents incorporated therein so that,
in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectuses, they
will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

(c)              
No Misstatement or Material Omission. The Agent shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s reasonable opinion is material,
or omits to state a fact that in the Agent’s opinion is material and is required to be stated therein or is necessary to make the
statements therein not misleading.

 

(d)             
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with or furnished
to the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital share of
the Company or any Material Adverse Effect, or any development that would reasonably be expected to cause a Material Adverse Effect the
effect of which, in the reasonable judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise
have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and
in the manner contemplated in the Prospectus.

 

(e)              
Legal Opinions. The Agent shall have received the opinions and letters of US Company Counsel and Canadian Company Counsel
required to be delivered pursuant to Section 7(m) on or before the date on which such delivery of such opinions and letters are
required pursuant to Section 7(m).

 

(f)              
Agent Counsel Legal Opinion. The Agent shall have received from Duane Morris LLP, counsel for the Agent, such opinion or
opinions, on or before the date on which the delivery of the US Company Counsel and Canadian Company Counsel legal opinions are required
pursuant to Section 7(m), with respect to such matters
as the Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they request for enabling
them to pass upon such matters.

    	 	23	 

     

    

(g)             
Comfort Letter. The Agent shall have received the Comfort Letter required to be delivered pursuant to Section 7(n) on
or before the date on which such delivery of such letter is required pursuant to Section 7(n).

 

(h)             
Representation Certificate. The Agent shall have received the certificate required to be delivered pursuant to Section
7(l) on or before the date on which delivery of such certificate is required pursuant to Section 7(l).

 

(i)               
No Suspension. Trading in the Common Shares shall not have been suspended on the Exchange and the Common Shares shall not
have been delisted from the Exchange.

 

(j)               
Other Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(l),
the Company shall use its commercially reasonable efforts to furnish to the Agent such appropriate further information, certificates and
documents as the Agent may reasonably request and which are usually and customarily furnished by an issuer of securities in connection
with a securities offering. All such information, certificates, and other documents will be in compliance with the provisions hereof.
The Company will furnish the Agent with such conformed copies of such information, certificates, and other documents as the Agent shall
reasonably request.

 

(k)             
Securities Act Filings Made. All filings with the Commission required by Form F-3 under the Securities Act to have been
filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such
filing by Form F-3. The Company shall have complied in all material respects with all requirements imposed upon it by the Securities
Act, as from time to time in force, and shall have filed on or before their respective due dates (giving effect to Rule 12b-25(b) under
the Exchange Act, provided that if the Company relies on Rule 12b-25(b) in respect of any report required to be filed under the Exchange
Act, such report shall have been filed) all reports and any definitive proxy or information statement required to be filed by the Company
with or furnished to the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act for a period of at least twelve
months prior to the date of the Placement.

 

(l)               
Approval for Listing. The Placement Shares shall either have been approved for listing on the Exchange, subject only to
notice of issuance, or the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to,
the issuance of any Placement Notice.

 

(m)            
No Termination Event. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant
to Section 13(a).

 

    	 	24	 

     

    

 

		11.	Indemnification and Contribution.

 

(a)              
 Company Indemnification. The Company agrees to indemnify and hold harmless the Agent, its partners, members, directors,
officers, employees and agents and each person, if any, who controls the Agent within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense whatsoever (including any and all investigative,
legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceedings
or any claim asserted), as incurred, joint or several, arising out of or based upon any untrue statement or alleged untrue statement of
a material fact contained in the Registration Statement (or any amendment thereto), or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement
or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus or the Prospectuses (or any amendment
or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; provided, however, that this indemnity agreement
shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly
for use in the Registration Statement (or any amendment thereto), or in any related Issuer Free Writing Prospectus or the Prospectuses
(or any amendment or supplement thereto).

 

(b)             
Agent Indemnification. The Agent agrees to indemnify and hold harmless the Company and its directors and each officer of
the Company who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against
any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 11(a), as incurred, but
only insofar as such loss, liability, claim, damage and expense arise out of or are based, directly or indirectly, upon untrue statements
or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto), the Prospectus
(or any amendment or supplement thereto) or any Free Writing Prospectus in reliance upon and in conformity with information furnished
to the Company in writing by the Agent expressly for use therein.

 

    	 	25	 

     

    

(c)               Procedure.
Any party that proposes to assert the right to be indemnified under this Section 11 will, promptly after receipt of notice of
commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties
under this Section 11, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers
served, but the omission to so notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it
might have to any indemnified party otherwise than under this Section 11 and (ii) any liability that it may have to any
indemnified party under the foregoing provision of this Section 11 unless, and only to the extent that, such omission results
in the forfeiture or material impairment of substantive rights or defenses by the indemnifying party. If any such action is brought
against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to
participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving
notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified,
to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the
indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the
indemnified party for any legal or other expenses except as provided below. The indemnified party will have the right to employ its
own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified
party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2)
the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or
other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or
potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying
party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the
indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action within a
reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements
and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying
party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the
reasonable fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one
time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the
indemnifying party promptly after the indemnifying party receives a written invoice relating to fees, disbursements and other
charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim
effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party,
settle or compromise or consent to the entry of any judgment in any pending or threatened claim,
action or proceeding relating to the matters contemplated by this Section 11 (whether or not any indemnified party is a party
thereto), unless such settlement, compromise or consent (1) includes an unconditional release of each indemnified party from all
liability arising out of such litigation, investigation, proceeding or claim and (2) does not include a statement as to or an
admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

    	 	26	 

     

    

(d)              Contribution.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing
paragraphs of this Section 11 is applicable in accordance with its terms but for any reason is held to be unavailable from
the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages
(including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of,
any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons
other than the Agent, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who
signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and
the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the
one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other
hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (net of
commissions to the Agent but before deducting expenses) received by the Company bear to the total compensation received by the Agent
(before deducting expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by
the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is
appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the
Company, on the one hand, and the Agent on the other hand, with respect to the statements or omission that resulted in such loss,
claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with
respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the
Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or
prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions
pursuant to this Section 11(d) were to be determined by pro rata allocation or by any other
method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by
an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above
in this Section 11(d) shall be deemed to include, for the purpose of this Section 11(d), any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent
consistent with Section 11(c) hereof. Notwithstanding the foregoing provisions of this Section 11(d), the Agent shall
not be required to contribute any amount in excess of the commissions received by them under this Agreement and no person found
guilty of fraudulent misrepresentation (within the meaning of Section 10(f) of the Securities Act) will be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 11(d), any person who
controls a party to this Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or
agents of the Agent, will have the same rights to contribution as that party, and each officer and director of the Company who
signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions
hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in
respect of which a claim for contribution may be made under this Section 11(d), will notify any such party or parties from
whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be
sought from any other obligation it or they may have under this Section 11(d) except to the extent that the failure to so
notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought.
Except for a settlement entered into pursuant to the last sentence of Section 11(c) hereof, no party will be liable for
contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to Section
11(c) hereof.

 

12.             
Representations and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 11
of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall
survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons,
or the Company (or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement
Shares and payment therefor or (iii) any termination of this Agreement.

 

    	 	27	 

     

    

 

		13.	Termination.

 

(a)    
The Agent may terminate this Agreement, by notice to the Company, as hereinafter specified at any time (1) if there has been, since
the time of execution of this Agreement or since the date as of which information is given in the Prospectuses any Material Adverse Effect,
or if any development that is reasonably expected to have a Material Adverse Effect has actually occurred and in the reasonable judgment
of the Agent makes it impractical or inadvisable to market the Placement Shares hereunder, (2) if there has occurred any material adverse
change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation
thereof or other calamity or crisis or any change or development involving a prospective change in national or international political,
financial or economic conditions, in each case the effect of which, in the reasonable judgment of the Agent, makes it impractical or inadvisable
to sell the Placement Shares hereunder, (3) if trading in the Common Shares has been suspended or limited by the Commission or the Exchange,
or if trading generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed on the Exchange,
(4) if any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market shall have occurred
and be continuing, (5) if a major disruption of securities settlements or clearance services in the United States shall have occurred
and be continuing, or (6) if a banking moratorium has been declared by either U.S. Federal or New York authorities. Any such termination
shall be without liability of any party to any other party except that the provisions of Section 9 (Expenses), Section 11 (Indemnification),
Section 12 (Survival of Representations), Section 18 (Applicable Law; Waiver of Jury Trial) and Section 19 (Consent
to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this
Agreement as provided in this Section 13(a), the Agent shall provide the required notice as specified in Section 14 (Notices).

 

(b)     
(i) The Company shall have the right, by giving five (5) days’ notice as hereinafter specified to terminate this Agreement
in its sole discretion at any time after the date of this Agreement.

 

(ii)              
If the Agent declines any commercially reasonable Placement Notice pursuant to Section 2 of this Agreement, then the Company
shall have the right to terminate this Agreement by giving written notice of termination to the Agent. Any such termination shall be effective
immediately upon a delivery of a termination notice by the Company to the Agent.

 

Any termination
pursuant to Section 13(b) shall be without liability of any party to any other party except that the provisions of Section 9,
Section 11, Section 12, Section 18 and Section 19 hereof shall remain in full force and effect notwithstanding
such termination.

 

(c)      
The Agent shall have the right, by giving five (5) days’ notice as hereinafter specified to terminate this Agreement in its
sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other
party except that the provisions of Section 9, Section 11, Section 12, Section 18 and Section 19 hereof
shall remain in full force and effect notwithstanding such termination.

 

(d)      Unless
earlier terminated pursuant to this Section 13, this Agreement shall automatically terminate upon the issuance and sale of
all of the Placement Shares through or to the Agent on the terms and subject to the conditions set forth herein, except that the
provisions of Section 9, Section 11, Section 12, Section 18 and Section 19 hereof shall remain in
full force and effect notwithstanding such termination.

 

    	 	28	 

     

    

(e)      
This Agreement shall remain in full force and effect unless terminated pursuant to Sections 13(a), (b), (c) or
(d) above or otherwise by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall
in all cases be deemed to provide that Section 9, Section 11, Section 12, Section 18 and Section 19 hereof
shall remain in full force and effect. Upon termination of this Agreement, the Company shall not have any liability to the Agent for any
discount, commission or other compensation with respect to any Placement Shares not otherwise sold by the Agent under this Agreement.

 

(f)      
Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that
such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company,
as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares
shall settle in accordance with the provisions of this Agreement.

 

14.             
Notices. All notices or other communications required or permitted to be given by any party to any other party pursuant
to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agent, shall be delivered to:

 

	 	Virtu
Americas LLC

                               One Liberty
Plaza

                               165 Broadway

                               New York,
NY 10006

                               Attention:
General Counsel

 

with a copy to:

 

	 	Duane Morris LLP

                         1540 Broadway

                         New York, NY 10036

                         Attention: Dean M.
Colucci

                         Telephone: (973) 424-2020

                         Email:
dmcolucci@duanemorris.com

 

 

    	 	29	 

     

    

 

And if to the Company, shall be delivered
to:

 

	 	Liquid Media Group Ltd.

#202, 5626 Larch Street

Vancouver, BC V6M 4E1

Canada

Attention: Ronald Thomson, Chief Executive
Officer

Email: rhomson@liquidmediagroup.co

 

with a copy to:

 

	 	Katten Muchin Rosenman LLP

575 Madison Avenue

New York, NY 10022

Attention: Jonathan Weiner

Email: jonathan.weiner@katten.com

 

Each party to this
Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.
Each such notice or other communication shall be deemed given (i) when delivered personally, by email, or by verifiable facsimile transmission
(with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the
next succeeding Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii)
on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid).
For purposes of this Agreement, “Business Day” shall mean any day on which the Exchange and commercial banks in the
City of New York are open for business.

 

An electronic communication
(“Electronic Notice”) shall be deemed written notice for purposes of this Section 14 if sent to the electronic
mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending
Electronic Notice receives confirmation of receipt by the receiving party. Any party receiving Electronic Notice may request and shall
be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”) which shall be sent to
the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.

 

    	 	30	 

     

    

15.             
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and
their respective successors and the affiliates, controlling persons, partners, members, officers, directors, employees and agents referred
to in Section 11 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors
and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement
without the prior written consent of the other party.

 

16.             
Adjustments for Stock Splits. The parties acknowledge and agree that all share- related numbers contained in this Agreement
shall be adjusted to take into account any share consolidation, stock split, stock dividend or similar event effected with respect to
the Common Shares.

 

17.             
Entire Agreement; Amendment; Severability. This Agreement, including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto, constitute the entire agreement of the parties with respect to the subject matter hereof and supersede
all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject
matter hereof. Neither this Agreement nor any term hereof may be amended except pursuant
to a written instrument executed by the Company and the Agent. In the event that any one or more of the provisions contained herein, or
the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction,
then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the
remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not
contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall
be in accordance with the intent of the parties as reflected in this Agreement.

    	 	31	 

     

    

18.             
GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH
PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

19.             
CONSENT TO JURISDICTION. The Company hereby submits to the non-exclusive jurisdiction of any U.S. federal or state court
located in the Borough of Manhattan, the City and County of New York, in any action, suit or proceeding arising out of or relating to
or based upon this Agreement or any of the transactions contemplated hereby, and irrevocably and unconditionally waive any objection to
the laying of venue of any such action, suit or proceeding in any such court and agree not to plead or claim in any such court that any
such action, suit or proceeding has been brought in an inconvenient forum. The Company represents and warrants that it has appointed CT
Corporation as its authorized agent (the “Authorized Agent”) in the Borough of Manhattan, the City and County of New
York upon which process may be served in any such action, suit or proceeding pursuant to a written agreement (each, an “Appointment
Agreement”), a true, complete and correct copy of which will be delivered to the Representatives on the Closing Date, further
represents and warrants that the Authorized Agent has agreed to act as such agent for service of process, and agrees that service of process
upon such Authorized Agent, and written notice of said service to the Company as provided in this Agreement shall be deemed in every respect
effective service of process upon the Company in any such action, suit or proceeding, and agrees to take any and all such action as may
be necessary to maintain such designation and appointment of such Authorized Agent in full force and effect for a period of ten years
from the date of this Agreement.

20.             
Judgment Currency. The obligation of the Company in respect of any sum due to the Agent under this Agreement shall, notwithstanding
any judgment in a currency other than U.S. dollars (the “Judgment Currency”), not be discharged until the first business
day following receipt by the Agent of any sum adjudged to be so due in the Judgment Currency on which (and only to the extent that) the
Agent may in accordance with normal banking procedures purchase U.S. dollars with the Judgment Currency; if the U.S. dollars so purchased
are less than the sum originally due to the Agent hereunder, the Company agrees, as a separate obligation and notwithstanding any such
judgment, to indemnify the Agent against such loss in respect of any sum due to the Agent from the Company. If the U.S. dollars so purchased
are greater than the sum originally due to the Agent hereunder, the Agent agrees to pay to the Company an amount equal to the excess
of the U.S. dollars so purchased over the sum originally due to the Agent hereunder.

    	 	32	 

     

    

21.             
Use of Information. The Agent may not use any information gained in connection with this Agreement and the transactions
contemplated by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved by the
Company. The Agent acknowledges that any information gained in connection with this Agreement and the transactions contemplated by this
Agreement are subject to confidentiality and other restrictions.

 

22.             
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument, and shall become effective when counterparts have been signed by each
party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any
signature is delivered by email delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature
page were an original thereof.

 

		23.	Effect of Headings.

 

The section, schedules
and exhibit headings herein are for convenience only and shall not affect the construction hereof.

 

		24.	Permitted Free Writing Prospectuses.

 

Each of the Company
and the Agent represents, warrants and agrees that, unless it obtains the prior consent of the other party, it has not made and will not
make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute
a “free writing prospectus,” as defined in Rule 405, required to be filed with the Commission. Any such free writing prospectus
consented to by the Agent or by the Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.”
The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an “issuer
free writing prospectus,” as defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable
to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping.

 

		25.	Absence of Fiduciary Relationship.

 

The Company acknowledges and agrees that:

 

(a)              
the Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each
transaction contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between
the Company or any of its respective affiliates, shareholders (or other equityholders), creditors or employees or any other party,
on the one hand, and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by
this Agreement, irrespective of whether or not the Agent has advised or is advising the Company on other matters, and the Agent has no
obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly set forth
in this Agreement;

 

    	 	33	 

     

    

(b)             
it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions
contemplated by this Agreement;

 

(c)              
the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this
Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;

(d)             
it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and the Agent has no obligation to disclose such interests and transactions to the Company by virtue of any
fiduciary, advisory or agency relationship or otherwise; provided that the Agent hereby agrees not to engage in any such transaction which
would cause its interests to be in direct conflict with the best interests of the Company; and

 

(e)              
it waives, to the fullest extent permitted by law, any claims it may have against the Agent for breach of fiduciary duty or alleged
breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agent shall not have
any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim or to any person
asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company, other than in respect
of the Agent’s obligations under this Agreement and to keep information provided by the Company to the Agent and its counsel confidential
to the extent not otherwise publicly-available.

 

		26.	Definitions.

 

As used in this Agreement, the following
terms have the respective meanings set forth

below:

 

“Applicable Time”
means (i) each Representation Date and (ii) the time of each sale of

any Placement Shares pursuant to this Agreement.

 

“Issuer Free
Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433, relating to the Placement
Shares that (1) is required to be filed with the Commission by the Company, (2) is a “road show” that is a “written
communication” within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt
from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not reflect
the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form
retained in the Company’s records pursuant to Rule 433(g) under the Securities Act.

 

    	 	34	 

     

    

“Rule 172,” “Rule 405,”
“Rule 415,” “Rule 424,” “Rule 424(b),” “Rule 430B,” and “Rule
433” refer to such rules under the Securities Act.

 

All references in this
Agreement to financial statements and schedules and other information that is “contained,” “included,” “stated”
or “set forth” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to
mean and include all such financial statements and schedules and other information that is incorporated by reference (including by way
of the Incorporated Documents) in the Registration Statement or the Prospectus, as the case may be.

 

All references in
this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to
include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other
than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission) shall be deemed
to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to “supplements”
to the Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials prepared in connection
with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States to the extent those materials
are reviewed and consented to in advance by the Company.

 

[Signature Page Follows]

 

 

    	 	35	 

     

    

If the foregoing correctly sets
forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon
this letter shall constitute a binding agreement between the Company and the Agent.

 

Very truly yours,

 

LIQUID MEDIA GROUP LTD.

By: /s/ Ronald Thomson

 

Name: Ronald Thomson

Title: Chief Executive Officer

 

CONFIRMED AND
ACCEPTED as of the date first-above written:

 

VIRTU AMERICAS LLC

By: /s/ Joshua R. Feldman

 

Name:  Joshua R. Feldman

Title: Managing Director

 

 

 

 

     

     

    

 

 

SCHEDULE 1

 

 

 

_____________________________

 

FORM OF PLACEMENT NOTICE

_____________________________

 

 

 

	 	From:	Liquid Media Group Ltd.
	 	 	 
	 	To:	Virtu Americas LLC
	 	 	 
	 	 	 
	 	Subject:	Placement Notice

 

Ladies and Gentlemen:

 

Pursuant to the
terms and subject to the conditions contained in the Sales Agreement between Liquid Media Group Ltd. a corporation formed under the Business
Corporations Act (British Columbia) (the “Company”) and Virtu Americas LLC (the “Agent”), dated
August [__], 2021, the Company hereby requests that the Agent sell up to ________ of the Company’s Common Shares, no par value per
share[, at a minimum market price of $________ per share, during the time period beginning [month, day, time] and ending on the earlier
of [month, day, time] or such time as all such shares are sold].

 

[ADDITIONAL SALES
PARAMETERS MAY BE ADDED, INCLUDING, BUT NOT LIMITED TO, SPECIFIC DATES THE SHARES MAY NOT BE SOLD ON, MAXIMUM AMOUNTS TO BE SOLD EACH
DAY OR THE MANNER IN WHICH SALES ARE TO BE MADE BY THE AGENT]

 

 

 

 

 

 

 

 

 

 

     

     

    

 

 

 

 

SCHEDULE 2

 

 

 

_____________________________

 

Notice Parties

_____________________________

 

 

The Company

[______]

 

 

The Agent

[______]

 

 

     

     

    

 

SCHEDULE 3

 

 

 

_____________________________

 

Compensation

_____________________________

 

 

The Company shall
pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount up to 3.0% of the gross proceeds from
each sale of Placement Shares.

 

 

     

     

    

EXHIBIT 7(l)

 

Form of Representation Date
Certificate

 

This Officer’s
Certificate (this “Certificate”) is executed and delivered in connection with Section 7(l) of the Sales Agreement
(the “Agreement”), dated August [__], 2021, and entered into between Liquid Media Group Ltd. (the “Company”)
and Virtu Americas LLC. All capitalized terms used but not defined herein shall have the meanings given to such terms in the Agreement.

The undersigned has carefully examined
the Registration Statement, the Prospectus, any supplements to the Prospectus (each as defined in the Agreement) and the Agreement and
hereby certifies, in the capacity set forth below, that:

 

1.                           
the representations and warranties of the Company in the Agreement are true and correct in all material respects on and as of the
date hereof and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied
at or prior to the date hereof (other than those conditions waived by the Agent);

 

2.                           
to the Company’s knowledge, no stop order suspending the effectiveness of the Registration Statement has been issued and
no proceedings for that purpose have been instituted or threatened; and

 

3.                            since
the date of the most recent financial statements included in the Prospectus (exclusive of any supplement thereto subsequent to the
date hereof), there has been no event or condition constituting a Material Adverse Effect, except as set forth in or contemplated in
the

Prospectus (exclusive of any supplement thereto
subsequent to the date hereof).

 

 

	 	LIQUID MEDIA GROUP LTD.
	 	 
	 	 
	 	By: ______________________________
	 	 
	 	Name: ____________________________
	 	 
	 	Title: _____________________________
	 	 
	 	Date: _____________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]